Home › Bladder Cancer › Nevada › Reno
Bladder Cancer clinical trials in Reno, NV
3 studies for Bladder Cancer are looking for participants at sites in and around Reno (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Saint Mary's Regional Medical Center, Reno
- Carson Tahoe Regional Medical Center, Carson City · 25 mi away
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
RecruitingPhase 3
- Renown Regional Medical Center, Reno
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
RecruitingPhase 3
- Renown Regional Medical Center, Reno
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY36 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA25 studies
- Baltimore, MD24 studies
- Philadelphia, PA23 studies
- Edison, NJ23 studies
- St. Louis, MO22 studies
- Chicago, IL21 studies
Other studies in Reno
- Non-Small Cell Lung Cancer16 studies
- Breast Cancer15 studies
- Lung Cancer9 studies
- Geographic Atrophy8 studies
- Macular Degeneration7 studies
- Cancer (all types)7 studies
- Ovarian Cancer6 studies
- Pancreatic Cancer5 studies
- Metastatic Cancer5 studies
- Colon Cancer5 studies
- Colorectal Cancer5 studies
- Rectal Cancer4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.